[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1878720T3 - Fremgangsmåde til frembringelse af chirale bicycloprolinater som intermediat til frembringelsen af peptidomimetiske protease-inhibitorer - Google Patents

Fremgangsmåde til frembringelse af chirale bicycloprolinater som intermediat til frembringelsen af peptidomimetiske protease-inhibitorer

Info

Publication number
DK1878720T3
DK1878720T3 DK07012485.4T DK07012485T DK1878720T3 DK 1878720 T3 DK1878720 T3 DK 1878720T3 DK 07012485 T DK07012485 T DK 07012485T DK 1878720 T3 DK1878720 T3 DK 1878720T3
Authority
DK
Denmark
Prior art keywords
bicycloprolinates
production
protease inhibitors
producing chiral
peptidomimetic protease
Prior art date
Application number
DK07012485.4T
Other languages
English (en)
Inventor
Nancy June Snyder
Xicheng Sun
Mark Joseph Tebbe
Frantz Victor
May Q Wang
Mai Yee Yvonne Yip
Ivan Collado
Cristina Garcia-Paredes
Ling Jin
Deqi Duo
John Irvin Glass
Samuel Raymond Parker Iii
Robert Edward Babine
Shu-Hui Chen
Jason Eric Lamar
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26923261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1878720(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of DK1878720T3 publication Critical patent/DK1878720T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK07012485.4T 2000-08-31 2001-08-31 Fremgangsmåde til frembringelse af chirale bicycloprolinater som intermediat til frembringelsen af peptidomimetiske protease-inhibitorer DK1878720T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22939800P 2000-08-31 2000-08-31
US27764101P 2001-03-21 2001-03-21
EP01968040A EP1320540B9 (en) 2000-08-31 2001-08-31 Peptidomimetic protease inhibitors

Publications (1)

Publication Number Publication Date
DK1878720T3 true DK1878720T3 (da) 2011-01-24

Family

ID=26923261

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07012485.4T DK1878720T3 (da) 2000-08-31 2001-08-31 Fremgangsmåde til frembringelse af chirale bicycloprolinater som intermediat til frembringelsen af peptidomimetiske protease-inhibitorer
DK01968040.4T DK1320540T5 (da) 2000-08-31 2001-08-31 Peptidomimetiske proteaseinhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK01968040.4T DK1320540T5 (da) 2000-08-31 2001-08-31 Peptidomimetiske proteaseinhibitorer

Country Status (36)

Country Link
US (5) US7820671B2 (da)
EP (9) EP1876173A1 (da)
JP (4) JP4689938B2 (da)
KR (10) KR20110088600A (da)
CN (7) CN101633636B (da)
AR (1) AR030591A1 (da)
AT (2) ATE483686T1 (da)
AU (2) AU2001288318B2 (da)
BR (1) BR0113666A (da)
CA (2) CA2697205C (da)
CL (1) CL2010000330A1 (da)
CY (2) CY1109216T1 (da)
CZ (1) CZ2003595A3 (da)
DE (4) DE20122915U1 (da)
DK (2) DK1878720T3 (da)
DZ (1) DZ3438A1 (da)
EA (2) EA011547B1 (da)
EC (2) ECSP034493A (da)
ES (4) ES2450815T3 (da)
HR (1) HRP20030139B8 (da)
HU (1) HUP0300855A3 (da)
IL (6) IL154671A0 (da)
LU (1) LU91960I2 (da)
MX (1) MXPA03001780A (da)
NO (4) NO329929B1 (da)
NZ (2) NZ569670A (da)
PE (1) PE20020474A1 (da)
PL (1) PL211019B1 (da)
PT (1) PT1320540E (da)
SI (1) SI1320540T1 (da)
SK (1) SK2492003A3 (da)
SV (1) SV2003000617A (da)
TW (6) TWI359144B (da)
UA (2) UA99895C2 (da)
WO (1) WO2002018369A2 (da)
ZA (1) ZA200301641B (da)

Families Citing this family (240)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA66767C2 (uk) * 1996-10-18 2004-06-15 Вертекс Фармасьютикалс Інкорпорейтед Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
ES2240446T3 (es) * 2000-04-03 2005-10-16 Vertex Pharma Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
OA12382A (en) 2000-05-26 2006-04-17 Novirio Pharmaceuticals Ltd Methods and compositions for treating flavivirusesand pestiviruses.
MXPA03000626A (es) 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
MXPA03000627A (es) 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
GB2368339B (en) 2000-10-26 2002-09-18 Yissum Res Dev Co Complex incorporating a plurality of antioxidants
US7241796B2 (en) * 2001-10-24 2007-07-10 Vertex Pharmaceuticals Inc. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
KR20110028665A (ko) 2002-04-11 2011-03-21 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｃ형 간염 바이러스 ｎｓ3-ｎｓ4 프로테아제의 억제제
US7041698B2 (en) * 2002-05-20 2006-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
WO2004026896A2 (en) * 2002-09-23 2004-04-01 Medivir Ab Hcv ns-3 serine protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
AU2004230946A1 (en) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2011203054B2 (en) * 2003-04-11 2012-04-26 Vertex Pharmaceuticals, Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
ES2297424T3 (es) 2003-05-21 2008-05-01 Boehringer Ingelheim International Gmbh Compuestos inhibidores de la hepatitis c.
SI2604620T2 (sl) 2003-05-30 2024-10-30 Gilead Pharmasset Llc Modificirani fluorirani nukleozidni analogi
WO2005007681A2 (en) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
JP2007505603A (ja) * 2003-09-12 2007-03-15 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド プロテアーゼ活性および肝障害のための動物モデル
TW200526686A (en) 2003-09-18 2005-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ES2361997T3 (es) 2003-09-22 2011-06-27 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos activos contra el virus de la hepatitis c.
CN101857631A (zh) 2003-10-10 2010-10-13 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
US7365092B2 (en) * 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ZA200602937B (en) * 2003-10-10 2007-06-27 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
AU2004285019B9 (en) 2003-10-27 2011-11-24 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease resistance mutants
MXPA06004723A (es) * 2003-10-27 2006-07-05 Vertex Pharma Combinacion para el tratamiento del hcv.
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
JP2007513971A (ja) 2003-12-11 2007-05-31 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３／ｎｓ４ａプロテアーゼの阻害剤
DE602005025855D1 (de) 2004-01-21 2011-02-24 Boehringer Ingelheim Pharma Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
CA2554999A1 (en) * 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AR048241A1 (es) * 2004-02-27 2006-04-12 Schering Corp Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c .
JP4874227B2 (ja) * 2004-02-27 2012-02-15 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼインヒビターとしての環状ｐ４’ｓを有する新規ケトアミド
US7342041B2 (en) 2004-02-27 2008-03-11 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2005085275A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
ZA200700030B (en) * 2004-06-08 2009-06-24 Vertex Pharma Pharmaceutical compositions
EP1771454B1 (en) 2004-07-20 2011-06-15 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
EP1804821A4 (en) * 2004-10-01 2009-07-15 Vertex Pharma INHIBITION OF HCV NS3-NS4A PROTEASE
TWI437990B (zh) 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
WO2006102243A2 (en) 2005-03-21 2006-09-28 Applera Corporation Alpha ketoamide compounds as cysteine protease inhibitors
EP1871365A2 (en) * 2005-04-12 2008-01-02 Romark Laboratories, L.C. Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
NZ563909A (en) 2005-05-13 2011-10-28 Virochem Pharma Inc Thiophene derivatives and their use for the treatment or prevention of flavivirus infections
MX2007015270A (es) 2005-06-02 2008-02-21 Schering Corp Combinacion de inhibidores de proteasa de virus de la hepatitis c con un agente tensioactivo.
CA2610167A1 (en) 2005-06-02 2006-12-07 Schering Corporation Administration of hcv protease inhibitors in combination with food to improve bioavailability
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
WO2007014924A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
SI1912997T1 (sl) 2005-07-29 2012-02-29 Tibotec Pharm Ltd Makrociklični inhibitorji virusa hepatitis C
WO2007014922A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
CN101273030B (zh) 2005-07-29 2012-07-18 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
CA2617099C (en) 2005-07-29 2014-03-25 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
ES2401661T3 (es) 2005-08-02 2013-04-23 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
DE602006013492D1 (de) 2005-08-19 2010-05-20 Vertex Pharma Verfahren und zwischenprodukte
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
JP5409008B2 (ja) 2005-11-11 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス改変体
EP2036920B1 (en) * 2006-01-11 2011-05-18 Seikagaku Corporation Cycloalkylcarbonylamino acid ester derivative and process for producing the same
JP3975226B2 (ja) * 2006-01-11 2007-09-12 生化学工業株式会社 シクロアルキルカルボニルアミノ酸誘導体及びその製造方法
JP4047365B2 (ja) * 2006-01-11 2008-02-13 生化学工業株式会社 シクロアルカンカルボキサミド誘導体及びその製造方法
WO2007083620A1 (ja) * 2006-01-20 2007-07-26 Kaneka Corporation β－アミノ－α－ヒドロキシ酸アミド誘導体の製造法
JP5436864B2 (ja) * 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む共結晶体およびそれを含む医薬組成物
MX2008011429A (es) * 2006-03-06 2008-09-18 Abbott Lab Composiciones y metodos de uso de ritonavir para tratar hcv.
MX2008011869A (es) * 2006-03-16 2008-12-03 Vertex Pharma Procedimientos e intermediarios para preparar compuestos estericos.
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
KR20140107691A (ko) * 2006-03-20 2014-09-04 버텍스 파마슈티칼스 인코포레이티드 의약 조성물
MX2008012225A (es) * 2006-03-23 2008-12-03 Schering Corp Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas.
WO2007120595A2 (en) * 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
NZ571826A (en) 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
JP2009538327A (ja) 2006-05-23 2009-11-05 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤である化合物および組成物
DE102006059317A1 (de) 2006-07-04 2008-01-10 Evonik Degussa Gmbh Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
CN102675279A (zh) 2006-11-15 2012-09-19 Viro化学制药公司 用于治疗或预防黄病毒属感染的噻吩类似物
EP2097402B1 (en) 2006-11-17 2014-04-09 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
EP2428204A3 (en) 2006-12-07 2012-07-04 Schering Corporation pH sensitive matrix formulation
WO2008074035A1 (en) * 2006-12-27 2008-06-19 Abbott Laboratories Hcv protease inhibitors and uses thereof
WO2008095058A1 (en) * 2007-02-01 2008-08-07 Taigen Biotechnology Co. Ltd. Hcv protease inhibitors
EP2118091B1 (en) 2007-02-08 2015-04-15 Janssen Sciences Ireland UC Pyrimidine substituted macrocyclic hcv inhibitors
MX2009008518A (es) 2007-02-09 2009-08-20 Irm Llc Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
JP2010519329A (ja) 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
DK2114924T3 (da) * 2007-02-27 2012-04-10 Vertex Pharma Co-krystaller og farmaceutiske sammensætninger omfattende disse
US20080255038A1 (en) * 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
CN101815533A (zh) 2007-05-04 2010-08-25 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
US20100254942A1 (en) * 2007-08-03 2010-10-07 Biotron Limited Hepatitis c antiviral compositions and methods
CL2008002549A1 (es) 2007-08-30 2010-09-03 Vertex Pharma Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv.
HRP20110637T1 (hr) 2007-09-14 2011-10-31 Schering Corporation Metoda liječenja pacijenata sa hepatitisom c
US20090082366A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
AR068756A1 (es) 2007-10-10 2009-12-02 Novartis Ag Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c
WO2009055467A2 (en) * 2007-10-24 2009-04-30 Virobay, Inc. Compounds that inhibit protease cathepsin s and hcv replication
US20090111757A1 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
ES2389994T3 (es) 2007-12-24 2012-11-05 Janssen R&D Ireland Indoles macrocíclicos como inhibidores del virus de la hepatitis C
DE102008009761A1 (de) 2008-02-19 2009-08-27 Bayer Materialscience Ag Verfahren zur Herstellung von Isocyanaten
EP2101173A1 (en) 2008-03-14 2009-09-16 Vivalis In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
CA2728226A1 (en) 2008-06-24 2010-01-21 Codexis, Inc. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010014744A1 (en) * 2008-07-29 2010-02-04 The Scripps Research Institute Inhibitors of hepatitis c virus infection
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
CN102300461B (zh) 2008-12-03 2015-04-22 普雷西迪奥制药公司 Hcv ns5a的抑制剂
CN104163816A (zh) 2008-12-03 2014-11-26 普雷西迪奥制药公司 Hcv ns5a的抑制剂
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
JP2012517478A (ja) 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
AU2010229795A1 (en) 2009-03-27 2011-10-13 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
UY32721A (es) 2009-06-23 2011-01-31 Gilead Sciences Ltd Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
NZ599133A (en) 2009-09-15 2013-10-25 Taigen Biotechnology Co Ltd Hcv protease inhibitors
TWI404269B (zh) * 2009-09-18 2013-08-01 Advanced Connectek Inc High speed plug connector
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
AU2010326225A1 (en) 2009-11-25 2012-06-07 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
US8362068B2 (en) * 2009-12-18 2013-01-29 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
CA2784036A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8653025B2 (en) 2010-01-27 2014-02-18 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
RU2012136824A (ru) 2010-01-29 2014-03-10 Вертекс Фармасьютикалз Инкорпорейтед Способы лечения вирусной инфекции гепатита с
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
AU2011232331A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
AU2011232348A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
EP2550262A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
MX2012011222A (es) 2010-04-01 2013-01-18 Centre Nat Rech Scient Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
AU2011261349A1 (en) 2010-06-03 2012-12-06 Vertex Pharmaceuticals Incorporated Processes and intermediates
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
EP2582717A2 (en) 2010-06-15 2013-04-24 Vertex Pharmaceuticals Incorporated Hcv ns5b polymerase mutants
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
MX2012014918A (es) 2010-06-28 2013-04-08 Vertex Pharma Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
US20120014912A1 (en) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition
AR082619A1 (es) 2010-08-13 2012-12-19 Hoffmann La Roche Inhibidores del virus de la hepatitis c
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
CA2815416A1 (en) 2010-10-21 2012-04-26 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
PH12013500770A1 (en) 2010-10-26 2018-01-17 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8680152B2 (en) 2011-05-02 2014-03-25 Virobay, Inc. Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
EP2707347A1 (en) 2011-05-13 2014-03-19 Vertex Pharmaceuticals Inc. Processes and intermediates
AU2012269643A1 (en) 2011-06-16 2014-02-06 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
CN103732242A (zh) 2011-06-23 2014-04-16 迪格纳生物技术公司 用与IFN-α2b组合的IFN-α5在患者群体中治疗慢性丙型肝炎
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
AR087345A1 (es) 2011-07-26 2014-03-19 Vertex Pharma Metodos para la preparacion de compuestos de tiofeno
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2760827A4 (en) 2011-09-27 2015-06-24 Univ Kansas State ANTIVIRAL MEDIUM WITH A WIDE SPECTRUM AGAINST 3C OR 3C-SIMILAR PROTEASES FROM PICORNIVIRUS SUPERCLUSTS: PICORNIVERS, CALICIVIRES AND CORONA VIRUSES
CN103917541B (zh) 2011-10-10 2016-08-17 弗·哈夫曼-拉罗切有限公司 抗病毒化合物
TWI633091B (zh) 2011-10-14 2018-08-21 Bristol-Myers Squibb Company 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
MX2014004727A (es) 2011-10-21 2014-07-28 Abbvie Inc Metodos para tratar el virus de la hepatitis c, que comprende al menos dos agentes antivirales que actuan de manera directa, ribavirina, pero no interferon.
MX2014006745A (es) 2011-12-16 2014-10-15 Hoffmann La Roche Inhibidores de hcv ns5a.
MY171577A (en) 2011-12-20 2019-10-21 Hoffmann La Roche 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EA024847B1 (ru) 2011-12-20 2016-10-31 Рибосайенс Ллк 4'-азидо,3'-фторзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гепатита с
MX340033B (es) 2011-12-28 2016-06-21 Janssen Sciences Ireland Uc Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
US20130195797A1 (en) 2012-01-31 2013-08-01 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
ITMI20120192A1 (it) 2012-02-13 2013-08-14 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi
EP2814807A4 (en) * 2012-02-16 2015-10-07 Rqx Pharmaceuticals Inc LINEAR PEPTIDANTIBIOTICS
WO2013124335A1 (en) 2012-02-24 2013-08-29 F. Hoffmann-La Roche Ag Antiviral compounds
ITMI20120359A1 (it) 2012-03-07 2013-09-08 Dipharma Francis Srl Procedimento per la preparazione di intermedi utili nella preparazione di un inibitore delle proteasi virali
ITMI20120391A1 (it) * 2012-03-13 2013-09-14 Dipharma Francis Srl Procedimento per la sintesi di un intermedio ciclopropilammidico utile nella preparazione di un inibitore delle proteasi virali
WO2013136265A1 (en) 2012-03-13 2013-09-19 Dipharma Francis S.R.L. Synthesis of an intermediate of an antiviral compound
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
US9309284B2 (en) 2012-05-02 2016-04-12 Kansas State University Reasearch Foundation Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, caliciviruses and coronaviruses
ITMI20120800A1 (it) * 2012-05-10 2013-11-11 Dipharma Francis Srl Procedimento per la preparazione di un intermedio utile nella preparazione di un inibitore delle proteasi virali
WO2013178682A2 (en) 2012-05-30 2013-12-05 Chemo Ibérica, S.A. Multicomponent process for the preparation of bicyclic compounds
CN103450066B (zh) * 2012-05-30 2017-03-15 博瑞生物医药（苏州）股份有限公司 特拉匹韦中间体的制备方法
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2014033667A1 (en) 2012-08-30 2014-03-06 Ranbaxy Laboratories Limited Process for the preparation of telaprevir
WO2014045263A2 (en) * 2012-09-24 2014-03-27 Dr. Reddy's Laboratories Limited Process for preparation of intermediates of telaprevir
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
BR112015007937A2 (pt) 2012-10-12 2017-07-04 Bristol Myers Squibb Co formas cristalinas de um inibidor de fator xia
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
ITMI20122036A1 (it) 2012-11-29 2014-05-30 Dipharma Francis Srl Sintesi di un intermedio di un composto antivirale
WO2014096374A1 (en) 2012-12-21 2014-06-26 Sandoz Ag Process for the synthesis of pyrrolidines and pyrroles
BR112015017414A2 (pt) 2013-01-23 2017-07-11 Hoffmann La Roche derivados de triazol antivirais
CN103113288B (zh) * 2013-02-04 2015-05-20 苏州永健生物医药有限公司 一种八氢环戊烯并[c]吡咯羧酸衍生物的合成方法
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
KR20150114566A (ko) 2013-03-05 2015-10-12 에프. 호프만-라 로슈 아게 항바이러스 화합물
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
ITMI20130706A1 (it) 2013-04-30 2014-10-31 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi
KR102241198B1 (ko) 2013-05-16 2021-04-15 리보사이언스 엘엘씨 4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체
JP2016519146A (ja) 2013-05-16 2016-06-30 リボサイエンス・エルエルシー ４’−アジド，３’−デオキシ−３’−フルオロ置換ヌクレオシド誘導体
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
CN104163851B (zh) * 2013-05-20 2019-03-05 湘北威尔曼制药股份有限公司 氟代的α-羰基类HCV NS3/4A丝氨酸蛋白酶抑制剂
CN103288671B (zh) * 2013-06-20 2014-10-29 上海步越化工科技有限公司 一种(3s)-3-氨基-n-环丙基-2-羟基己酰胺盐酸盐的合成方法
WO2014203224A1 (en) 2013-06-21 2014-12-24 Ranbaxy Laboratories Limited Process for the preparation of telaprevir and its intermediates
WO2014203208A1 (en) 2013-06-21 2014-12-24 Ranbaxy Laboratories Limited Process for the preparation of telaprevir and intermediates thereof
CN104292146B (zh) * 2013-06-24 2017-04-26 上海医药工业研究院 特拉匹韦中间体及其制备方法
CN104558106B (zh) * 2013-10-19 2019-12-10 广东东阳光药业有限公司 一种治疗丙肝药物的制备方法
CN104610272B (zh) * 2013-11-05 2017-03-29 上海唐润医药科技有限公司 环状黄酮或异黄酮类化合物及其用途
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
NO2760821T3 (da) 2014-01-31 2018-03-10
EP3099686B1 (en) 2014-01-31 2020-03-11 Bristol-Myers Squibb Company Macrocycles with aromatic p2' groups as factor xia inhibitors
CN104926712B (zh) * 2014-03-20 2018-03-23 上海医药工业研究院 合成特拉匹韦的中间体及其制备方法
CN104926831A (zh) * 2014-03-20 2015-09-23 上海医药工业研究院 合成特拉匹韦的中间体及其制备方法
NO346949B1 (en) 2014-07-07 2023-03-13 Halliburton Energy Services Inc Downhole tools comprising aqueous-degradable sealing elements, a method, and a system
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3423467B1 (en) 2016-03-04 2021-04-28 F. Hoffmann-La Roche AG New difluoroketamide derivatives as htra1 inhibitors
CN108699106B (zh) 2016-03-04 2021-11-30 豪夫迈·罗氏有限公司 作为htra1抑制剂的新型三氟甲基丙酰胺衍生物
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
DK3472149T3 (da) 2016-06-21 2023-11-27 Orion Ophthalmology LLC Heterocykliske prolinamidderivater
WO2017222917A1 (en) * 2016-06-21 2017-12-28 Inception 4, Inc. Aliphatic prolinamide derivatives
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
WO2018036942A1 (en) * 2016-08-23 2018-03-01 F. Hoffmann-La Roche Ag New difluoroketamide derivatives as htra1 inhibitors
SG11202002431SA (en) 2017-09-21 2020-04-29 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
CN109337537B (zh) * 2018-09-26 2022-10-25 河北晨阳工贸集团有限公司 一种起重机专用单组分水性面漆及其制备方法
CN110668538B (zh) * 2019-09-20 2021-10-22 济南大学 一种聚合氯化钛的制备方法
CN115960088B (zh) * 2020-07-31 2024-07-26 四川大学 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途
CN114057702B (zh) * 2020-07-31 2022-09-30 四川大学 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
WO2023149981A1 (en) * 2022-02-07 2023-08-10 Purdue Research Foundation Compounds for the treatment of sars
CN114703003B (zh) * 2022-04-14 2023-04-28 上海绿晟环保科技有限公司 一种负载碳量子点的纳米材料润滑添加剂及其制备方法
CN115417790A (zh) * 2022-10-09 2022-12-02 山东大学 一类新型偶氮类发泡剂及合成方法

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
FR2570695A1 (fr) * 1984-09-27 1986-03-28 Synthelabo Diphenylazomethines a chaine ramifiee ou cyclique, leur preparation et leur application en therapeutique
FR2575753B1 (fr) 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5496927A (en) 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
EP0204571B1 (en) * 1985-06-07 1992-01-22 Ici Americas Inc. Selected difluoro derivatives
US4835168A (en) 1985-12-16 1989-05-30 Eli Lilly And Company Thiadiazole antiviral agents
US5231084A (en) 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
US5736520A (en) 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
DE69329544T2 (de) 1992-12-22 2001-05-31 Eli Lilly And Co., Indianapolis HIV Protease hemmende Verbindungen
DE69334250D1 (de) 1992-12-29 2009-01-29 Abbott Lab Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
US5384410A (en) 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5656600A (en) * 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
IL113196A0 (en) 1994-03-31 1995-06-29 Bristol Myers Squibb Co Imidazole derivatives and pharmaceutical compositions containing the same
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
JPH09124691A (ja) * 1995-08-25 1997-05-13 Green Cross Corp:The ペプチド化合物およびそれを含有する医薬組成物
WO1997019084A1 (en) 1995-11-23 1997-05-29 Merck Sharp & Dohme Limited Spiro-piperidine derivatives and their use as tachykinin antagonists
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
TR199802136T2 (xx) 1996-04-23 2001-06-21 Vertex Pharmaceuticals Incorporated �MPDH enzimi inhibit�rleri olarak �re t�revleri.
US6127422A (en) 1996-05-06 2000-10-03 Eli Lilly And Company Anti-viral method
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
WO1997043310A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
CN1218479A (zh) 1996-05-17 1999-06-02 咨询卡有限公司 可固化的表面涂层组合物及其使用方法
EP0913389A4 (en) * 1996-06-28 2000-02-02 Nippon Chemiphar Co CYCLOPROPYLGLYCINE DERIVATIVES AND AGONISTS OF THE L-GLUTAMATE RECEPTOR TYPE OF METABOLITE REGULATION
US6245919B1 (en) 1996-06-28 2001-06-12 Haruhiko Shinozaki Cyclopropylglycine derivatives and agonists for metabotronic L-glutamate receptors
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
WO1998013369A1 (en) 1996-09-25 1998-04-02 Merck Sharp & Dohme Limited Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists
JP2001502316A (ja) 1996-10-08 2001-02-20 コロラド ステート ユニバーシティ リサーチ ファンデーション 触媒不斉エポキシ化
UA66767C2 (uk) 1996-10-18 2004-06-15 Вертекс Фармасьютикалс Інкорпорейтед Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE19648011A1 (de) 1996-11-20 1998-05-28 Bayer Ag Cyclische Imine
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
GB9708484D0 (en) 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
GB9711114D0 (en) 1997-05-29 1997-07-23 Merck Sharp & Dohme Therapeutic agents
PT1003775E (pt) 1997-08-11 2005-07-29 Boehringer Ingelheim Ca Ltd Peptidos inibidores da hepatite c
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
US6183121B1 (en) 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
AU1416099A (en) 1997-11-28 1999-06-16 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
DK1066247T3 (da) 1998-03-31 2007-04-02 Vertex Pharma Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
US6518305B1 (en) * 1998-04-23 2003-02-11 Abbott Laboratories Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases
US6251583B1 (en) 1998-04-27 2001-06-26 Schering Corporation Peptide substrates for HCV NS3 protease assays
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
US6117639A (en) 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
US6025516A (en) 1998-10-14 2000-02-15 Chiragene, Inc. Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
ATE400251T1 (de) 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
US20020042046A1 (en) 1999-02-25 2002-04-11 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
EA004141B1 (ru) 1999-03-19 2004-02-26 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фермента impdh
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
US20020183249A1 (en) 1999-08-31 2002-12-05 Taylor Neil R. Method of identifying inhibitors of CDC25
CA2390349A1 (en) 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
US6365380B2 (en) * 2000-02-23 2002-04-02 Pcbu Services, Inc. Method for stereoselectively inverting a chiral center of a chemical compound using an enzyme and a metal catalyst
WO2001064678A2 (en) 2000-02-29 2001-09-07 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
ES2240446T3 (es) 2000-04-03 2005-10-16 Vertex Pharma Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
JP4748911B2 (ja) 2000-04-05 2011-08-17 シェーリング コーポレイション Ｎ−環状ｐ２部分を含むｃ型肝炎ウイルスの大環状ｎｓ３‐セリンプロテアーゼ阻害剤
BR0110104A (pt) 2000-04-19 2003-01-07 Schering Corp Inibidores de ns-3 serina rotease macrocìclica do vìrus da hepatite c compreendendo porções de alquil e aril alanina p2
EP2289887A3 (en) 2000-06-30 2011-07-06 Seikagaku Corporation Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
MXPA03000627A (es) 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
AU2001277967A1 (en) 2000-07-21 2002-02-05 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
MXPA03000626A (es) 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6939692B2 (en) 2000-09-12 2005-09-06 Degussa Ag Nucleotide sequences coding for the pknB gene
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
BR0115447A (pt) 2000-11-20 2005-10-18 Bristol Myers Squibb Co Inibidores de tripeptìdeo de hepatite c
AU2002236591B2 (en) 2000-12-12 2005-07-14 Schering Corporation Diaryl peptides as NS3-serine protease inhibitors of hepatits C virus
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
CN1267446C (zh) 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
EP1356123A2 (en) 2001-01-30 2003-10-29 Vertex Pharmaceuticals Incorporated A quantitative assay for nucleic acids
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
EP1381673B1 (en) 2001-03-27 2009-05-13 Vertex Pharmaceuticals Incorporated Compositions and methods useful for hcv infection
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
EP1463699A2 (en) 2001-07-03 2004-10-06 ALTANA Pharma AG Process for the production of 3-phenylisoserine
CN100402549C (zh) 2001-07-11 2008-07-16 沃泰克斯药物股份有限公司 桥连二环的丝氨酸蛋白酶抑制剂
US7029561B2 (en) 2001-07-25 2006-04-18 The United States Of America As Represented By The Secretary Of Commerce Fluidic temperature gradient focusing
JP2003055389A (ja) 2001-08-09 2003-02-26 Univ Tokyo 錯体及びそれを用いたエポキシドの製法
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
US7241796B2 (en) 2001-10-24 2007-07-10 Vertex Pharmaceuticals Inc. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP1458693A4 (en) 2001-11-14 2005-02-09 Teva Pharma Amorphous and crystalline forms of losartan potassium and method for making same
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
KR20110028665A (ko) 2002-04-11 2011-03-21 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｃ형 간염 바이러스 ｎｓ3-ｎｓ4 프로테아제의 억제제
EP1545545A4 (en) 2002-08-01 2008-09-03 Pharmasset Inc COMPOUNDS WITH THE BICYCLO 4.2.1 NONAN SYSTEM FOR THE TREATMENT OF FLAVIVIRIDAE / I INFECTIONS
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
CA2413705A1 (en) 2002-12-06 2004-06-06 Raul Altman Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
MXPA05008106A (es) 2003-02-18 2005-09-21 Pfizer Inhibidores del virus de la hepatitis c, composiciones y tratamientos que los emplean.
JP4550824B2 (ja) 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎抑制化合物
US6908901B2 (en) 2003-03-05 2005-06-21 Boehringer Ingelheim International, Gmbh Hepatitis C inhibitor peptide analogs
AU2004230946A1 (en) 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ES2297424T3 (es) 2003-05-21 2008-05-01 Boehringer Ingelheim International Gmbh Compuestos inhibidores de la hepatitis c.
WO2005007681A2 (en) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
JP2007505603A (ja) 2003-09-12 2007-03-15 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド プロテアーゼ活性および肝障害のための動物モデル
TW200526686A (en) 2003-09-18 2005-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US6933760B2 (en) 2003-09-19 2005-08-23 Intel Corporation Reference voltage generator for hysteresis circuit
ES2361997T3 (es) 2003-09-22 2011-06-27 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos activos contra el virus de la hepatitis c.
CN101857631A (zh) 2003-10-10 2010-10-13 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
US7365092B2 (en) 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AR045870A1 (es) 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
MXPA06004723A (es) 2003-10-27 2006-07-05 Vertex Pharma Combinacion para el tratamiento del hcv.
AU2004285019B9 (en) 2003-10-27 2011-11-24 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease resistance mutants
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
JP4942485B2 (ja) 2003-10-28 2012-05-30 バーテックス ファーマシューティカルズ インコーポレイテッド Ｆｉｓｃｈｅｒ−ｆｉｎｋ型合成および続くアシル化による４，５−ジアルキル−３−アシル−ピロール−２−カルボン酸誘導体の製造
US20050119318A1 (en) 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005054450A1 (en) 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Compositions comprising fetal liver cells and methods useful for hcv infection
DE602005025855D1 (de) 2004-01-21 2011-02-24 Boehringer Ingelheim Pharma Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
CA2554999A1 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EA013207B1 (ru) 2004-02-20 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
US7342041B2 (en) 2004-02-27 2008-03-11 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease
RU2433127C2 (ru) 2004-03-12 2011-11-10 Вертекс Фармасьютикалз Инкорпорейтед Способы и промежуточные продукты
US20050249702A1 (en) 2004-05-06 2005-11-10 Schering Corporation (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
ZA200700030B (en) 2004-06-08 2009-06-24 Vertex Pharma Pharmaceutical compositions
ATE513844T1 (de) 2004-08-27 2011-07-15 Schering Corp Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
ES2401661T3 (es) 2005-08-02 2013-04-23 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas
DE602006013492D1 (de) 2005-08-19 2010-05-20 Vertex Pharma Verfahren und zwischenprodukte
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
JP5436864B2 (ja) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む共結晶体およびそれを含む医薬組成物
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
MX2008011869A (es) 2006-03-16 2008-12-03 Vertex Pharma Procedimientos e intermediarios para preparar compuestos estericos.
KR20140107691A (ko) 2006-03-20 2014-09-04 버텍스 파마슈티칼스 인코포레이티드 의약 조성물
TW200812611A (en) 2006-03-20 2008-03-16 Vertex Pharma Pharmaceutical compositions
PT2037887E (pt) 2006-05-31 2010-12-07 Vertex Pharma Formulações orais de libertação controlada de um inibidor da enzima conversora de interleucina-1 beta
JP2010519329A (ja) 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤

Also Published As

Publication number Publication date
DE20122915U1 (de) 2010-04-08
ES2489115T3 (es) 2014-09-01
EP1320540A2 (en) 2003-06-25
IL154671A (en) 2011-11-30
IL215891A0 (en) 2011-12-29
EP1849797A2 (en) 2007-10-31
ATE483686T1 (de) 2010-10-15
ES2325481T3 (es) 2009-09-07
NO20100093L (no) 2003-04-16
EP2368878A1 (en) 2011-09-28
JP4689938B2 (ja) 2011-06-01
CL2010000330A1 (es) 2010-09-21
LU91960I2 (fr) 2012-05-21
AU2001288318B2 (en) 2007-09-06
CY1109216T1 (el) 2014-07-02
HK1057758A1 (en) 2004-04-16
HK1163061A1 (en) 2012-09-07
CN103232381A (zh) 2013-08-07
TW201022242A (en) 2010-06-16
CN102504014A (zh) 2012-06-20
EP2368877B1 (en) 2014-05-07
DK1320540T5 (da) 2012-05-29
US8252923B2 (en) 2012-08-28
KR100876472B1 (ko) 2008-12-31
HRP20030139A2 (en) 2005-04-30
NO329929B1 (no) 2011-01-24
DE60138717D1 (de) 2009-06-25
CY2012007I2 (el) 2014-07-02
TW200918523A (en) 2009-05-01
PL365836A1 (en) 2005-01-10
BR0113666A (pt) 2005-09-27
JP2011079835A (ja) 2011-04-21
KR20110088600A (ko) 2011-08-03
NO20030928D0 (no) 2003-02-27
DK1320540T3 (da) 2009-07-27
AU8831801A (en) 2002-03-13
ZA200301641B (en) 2004-06-21
PE20020474A1 (es) 2002-06-18
CA2697205A1 (en) 2002-03-07
IL215892A0 (en) 2011-12-29
TW201022241A (en) 2010-06-16
EA200701869A1 (ru) 2008-02-28
ES2352804T3 (es) 2011-02-23
HK1114090A1 (en) 2008-10-24
SI1320540T1 (sl) 2009-10-31
JP2004517047A (ja) 2004-06-10
US20120282219A1 (en) 2012-11-08
HRP20030139B1 (hr) 2015-08-28
KR20100043293A (ko) 2010-04-28
CN101693672B (zh) 2014-11-12
WO2002018369A8 (en) 2003-11-06
CN1451014A (zh) 2003-10-22
US7820671B2 (en) 2010-10-26
CN101633636B (zh) 2013-03-13
EP1878720B1 (en) 2010-10-06
AU2001288318C1 (en) 2002-03-13
EA011547B1 (ru) 2009-04-28
JP5269035B2 (ja) 2013-08-21
UA99895C2 (uk) 2012-10-25
US20140294763A1 (en) 2014-10-02
CN101633636A (zh) 2010-01-27
TW201022243A (en) 2010-06-16
NZ569670A (en) 2010-03-26
CN1869061A (zh) 2006-11-29
EP1876173A1 (en) 2008-01-09
TWI319763B (en) 2010-01-21
ECSP077217A (es) 2007-04-26
HUP0300855A2 (hu) 2003-10-28
SK2492003A3 (en) 2004-11-03
KR20080104382A (ko) 2008-12-02
KR20100042296A (ko) 2010-04-23
CA2419607A1 (en) 2002-03-07
CZ2003595A3 (cs) 2003-06-18
IL215892A (en) 2015-03-31
KR20030041981A (ko) 2003-05-27
HUP0300855A3 (en) 2012-01-30
AR030591A1 (es) 2003-08-27
DE122012000015I1 (de) 2012-05-24
KR20080104383A (ko) 2008-12-02
IL215890A0 (en) 2011-12-29
US20120064034A1 (en) 2012-03-15
US20100137583A1 (en) 2010-06-03
JP2007284444A (ja) 2007-11-01
IL154671A0 (en) 2003-09-17
CA2419607C (en) 2012-03-13
EP2371839A1 (en) 2011-10-05
DZ3438A1 (fr) 2002-03-07
KR20080007515A (ko) 2008-01-21
IL185644A0 (en) 2008-01-06
KR100968295B1 (ko) 2010-07-07
CN100522991C (zh) 2009-08-05
ES2325481T9 (es) 2012-07-10
US8529882B2 (en) 2013-09-10
KR20080104384A (ko) 2008-12-02
ECSP034493A (es) 2003-04-25
HRP20030139B8 (hr) 2015-11-06
MXPA03001780A (es) 2003-06-04
NO2012006I2 (no) 2012-04-03
JP2012197289A (ja) 2012-10-18
KR20090120013A (ko) 2009-11-23
KR20080096718A (ko) 2008-10-31
NO20100999L (no) 2003-04-16
NZ541302A (en) 2007-04-27
CA2697205C (en) 2014-07-29
CN1869061B (zh) 2013-04-24
EP1849797A3 (en) 2008-01-23
EP1320540B1 (en) 2009-05-13
TWI378927B (en) 2012-12-11
EP2368901A1 (en) 2011-09-28
WO2002018369A3 (en) 2002-08-15
PT1320540E (pt) 2009-07-14
PL211019B1 (pl) 2012-03-30
TWI339661B (en) 2011-04-01
US20050197299A1 (en) 2005-09-08
ATE431358T1 (de) 2009-05-15
DE60143233D1 (de) 2010-11-18
EA200300318A1 (ru) 2004-02-26
NO330807B1 (no) 2011-07-18
TW201022244A (en) 2010-06-16
TWI359144B (en) 2012-03-01
EP2368877A1 (en) 2011-09-28
UA81600C2 (en) 2008-01-25
EP1878720A1 (en) 2008-01-16
WO2002018369A2 (en) 2002-03-07
IL215891A (en) 2015-04-30
TWI359145B (en) 2012-03-01
ES2450815T3 (es) 2014-03-25
SV2003000617A (es) 2003-01-13
CN101693672A (zh) 2010-04-14
KR100945975B1 (ko) 2010-03-09
EP1320540B9 (en) 2012-03-21
NO2012006I1 (no) 2012-04-30
EA017556B1 (ru) 2013-01-30
EP1958956A3 (en) 2008-09-24
NO20030928L (no) 2003-04-16
EP1958956B1 (en) 2013-12-11
EP1958956A2 (en) 2008-08-20
CN101696232A (zh) 2010-04-21
CY2012007I1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
DK1878720T3 (da) Fremgangsmåde til frembringelse af chirale bicycloprolinater som intermediat til frembringelsen af peptidomimetiske protease-inhibitorer
DK1383731T3 (da) Biarylforbindelser som serinproteaseinhibitorer
IS5884A (is) Aðferð til framleiðslu á hreinu sítalóprami
NO20043345L (no) Fremgangsmate for fremstilling av hydrokarboner
IS6487A (is) Aðferð til framleiðslu á Sítalóprami
IS7239A (is) Aðferð til framleiðslu á essítalóprami
IS7909A (is) Aðferð til að framleiða ljósfræðilega hrein virk efnasambönd
NO20026116L (no) Fremgangsmåte for fremstilling av blokkskum
ATE373485T1 (de) Herstellungsverfahren für kombinationsimpfstoffe
NO20031413D0 (no) Ny fremgangsmåte for fremstilling av oksabispidiner
EP1594505A4 (en) PHENYLGLYCIN DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS
PL377943A1 (pl) Sposób wytwarzania benzofenonów
AU2003258667A1 (en) Method for the production by fermentation of sulphur-containing fine chemicals (metf)
ATE465155T1 (de) Verfahrensherstellung von ethern
IS2674B (is) Aðferð við framleiðslu á handhverfulega hreinu mírtasapíni
NO20044050L (no) Fremgangsmate for syntese av chirale N-aryl-piperaziner
AR028078A1 (es) Proceso para la produccion de grrnulos de enzimas
NO20041224L (no) Fremgangsmate for fremstilling av hydrokarboner
DK1692137T3 (da) Fremgangsmåde til fremstilling af tubulinininhibitorer
ITMI20030346A1 (it) Procedimento per la produzione di mesitilene.
IL175528A0 (en) Methods of preparing compounds useful as protease inhibitors
DK1274677T3 (da) Fremgangsmåde til fremstilling af oximethere
DK1373245T3 (da) Mellemprodukter til fremstilling af spinosyner
ITMI20010914A0 (it) Processo per la produzione di alcool 5-benzil-3-furfurilico
ITAN20030003A1 (it) Metodo per la realizzazione di caldaie per la produzione